Effectiveness of influenza vaccine in preventing severe cases of influenza: Season 2022/2023

Guillermo Platas-Abenza,María Guerrero-Soler,Raissa de Fatima Silva-Afonso,Pilar Gallardo-Rodriguez,Francisco Gil-Sánchez,Isabel Escribano-Cañadas,Carmen M Benito-Miralles,Noemi Solis-Aniorte,Rocio Carnicer-Bueno,Ana Esclapez-Martínez,Pablo Chico-Sánchez,José Sánchez-Payá,Paula Gras-Valentí

DOI: https://doi.org/10.1016/j.eimce.2023.12.001

Abstract:Introduction: Influenza poses a significant burden in terms of morbidity and mortality, with vaccination being one of the most effective measures for its prevention. Therefore, the aim of this study is to determine the effectiveness of the influenza vaccine in preventing cases of severe influenza in patients admitted to a tertiary hospital during the 2022/23 season. Methods: Case-control study. All hospitalised patients with a positive result in an RT-PCR for influenza were included. Those who met the criteria for a severe case (pneumonia, sepsis, multi-organ failure, admission to ICU or exitus) were considered cases. Those who did not meet these criteria were considered controls. Vaccine effectiveness (VE) to prevent severe cases and its 95% confidence interval were calculated. Results: A total of 403 patients were admitted with confirmed influenza. Of these, 98 (24.3%) developed severe influenza. Of the total, 50.6% were men and 47.1% were over 65 years of age. VE adjusted for influenza type, age and certain comorbidities was 40.6% (-21.9 to 71.1). In a segmented analysis, influenza vaccine was effective in preventing severe cases in all categories. It was particularly relevant in the 65+ age group (VEa = 60.9%; -2.0 to 85.0) and in patients with influenza A (VEa = 56.7%; 1.5-80.9). Conclusion: Influenza vaccination markedly reduced the occurrence of severe cases of influenza in hospitalised patients, therefore, it remains the main strategy to reduce morbidity and mortality and associated costs.